Virus aggregating peptide enhances the cell-mediated response to influenza virus vaccine

Highlights ► EB peptide induces influenza virus aggregation and enhanced uptake by macrophages. ► Addition of the EB peptide to inactivated influenza vaccine enhances protection. ► EB adjuvant enhances IFN-γ production and cell-mediated immune responses.

Saved in:
Bibliographic Details
Published in:Vaccine 2011-10, Vol.29 (44), p.7696-7703
Main Authors: Jones, Jeremy C, Settles, Erik W, Brandt, Curtis R, Schultz-Cherry, Stacey
Format: Article
Language:English
Subjects:
additives
Adjuvant
adjuvants
Adjuvants, Immunologic - administration & dosage
Allergy and Immunology
Animals
antibodies
Antibodies, Viral - blood
antiviral properties
Applied microbiology
Avian flu
Biological and medical sciences
Cell-mediated immunity
Colleges & universities
Cytokines
Eggs
Female
Fundamental and applied biological sciences. Psychology
H5N1 influenza virus
immune response
Immune system
Inactivated influenza vaccine
influenza
Influenza Vaccines - immunology
Influenza virus
interferon-gamma
Interferon-gamma - metabolism
Laboratory animals
Leukocytes, Mononuclear - immunology
Mice
Mice, Inbred BALB C
Microbiology
Miscellaneous
morbidity
Mortality
Orthomyxoviridae
Orthomyxoviridae Infections - immunology
Orthomyxoviridae Infections - pathology
Orthomyxoviridae Infections - prevention & control
Peptides
Peptides - administration & dosage
Phagocytosis
Spleen - immunology
splenocytes
Sucrose
Swine flu
vaccination
Vaccines
Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)
Vaccines, Inactivated - immunology
virion
Virology
Viruses
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Highlights ► EB peptide induces influenza virus aggregation and enhanced uptake by macrophages. ► Addition of the EB peptide to inactivated influenza vaccine enhances protection. ► EB adjuvant enhances IFN-γ production and cell-mediated immune responses.
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2011.07.133